Loading...
01/11 03:17
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call shows mixed signals: positive revenue growth and strategic initiatives, but concerns about supply chain disruptions and competitive pressures. While there is a clear path to profitability, the current financials show a net loss and reduced gross margins. The absence of clear shareholder return plans and the absence of positive analyst sentiment in the Q&A further support a neutral outlook. Without market cap data, the stock's sensitivity to these factors is uncertain, suggesting a neutral prediction for the stock price over the next two weeks.
Revenue $12.5 million, an 8% year-over-year increase. Growth was driven primarily by higher glaucoma probe sales and PASCAL system sales, partially offset by lower surgical retina probe sales.
Retina Product Revenue $6.7 million, a 4% year-over-year increase. This was driven primarily by higher PASCAL system sales, medical and surgical retina system sales, partially offset by a decrease in surgical retina probe sales.
Cyclo G6 Glaucoma Product Revenue $3.5 million, a 13% year-over-year increase. Growth was driven by increased sales of glaucoma probes and consoles.
Other Revenue $2.2 million, an increase of $0.2 million compared to $2.0 million in the third quarter of 2024. This was driven primarily by an increase in service revenue.
Gross Profit $4.0 million or a gross margin of 32.1%, a decrease of $0.3 million compared to $4.3 million or a gross margin of 37.3% in the third quarter of 2024. The gross margin decreased by 520 basis points due to a $0.8 million charge to cost of goods sold related to an inventory write-down, partially offset by a more favorable geographic and product mix.
Operating Expenses $5.4 million, a decrease of $0.8 million or 12% compared to $6.2 million in the third quarter of 2024. This was due to expense reduction measures taken in late 2024.
Net Loss $1.6 million or $0.09 per share, compared to a net loss of $1.9 million or $0.12 per share in the same period of the prior year. The improvement was driven by expense reduction measures.
Non-GAAP Adjusted EBITDA A loss of $131,000, an improvement of $1.3 million compared to a loss of $1.4 million in the third quarter of 2024. The improvement was driven primarily by expense reduction measures implemented in late 2024.
Cash and Cash Equivalents $5.6 million at the end of the third quarter of 2025, a reduction of $1.2 million compared to $6.8 million at the second quarter of 2025. The reduction reflects ongoing cash usage.
Cyclo G6 system: Sales increased to 30 units from 26 in the prior year period, with most units sold to existing users expanding into new locations. 14,900 probes were sold compared to 13,600 in the prior year period, indicating higher utilization in both the U.S. and internationally. ASPs for both probes and consoles increased.
PASCAL system: Sales remained strong in the U.S., with a focus on promoting the next-generation platform. Internationally, strong performance was noted in the Middle East and Africa, while Europe faced challenges due to MDR certification delays.
Geographic expansion: Positive contributions in Europe, Middle East, and Africa for glaucoma probe sales. Latin America and Canada showed improved momentum due to new glaucoma distributors and stronger partner engagement.
Cost reduction initiatives: Operating expenses reduced by 12% year-over-year in Q3 2025 and by 25% for the first 9 months of 2025. Relocation of certain functions outside California is expected to save $165,000 quarterly starting Q1 2026.
Manufacturing optimization: Negotiations with contract manufacturers to reduce cost of goods sold and improve gross margins. Transition of product lines to third-party manufacturers is ongoing.
Profitability focus: Achieved fourth consecutive quarter of year-over-year revenue growth and improved adjusted EBITDA. On track for positive cash flows in Q4 2025 and sustained cash flow positivity in 2026.
Supply Chain Disruptions: The company faced supply constraints in Q2, which deferred several orders to Q3. Additionally, the ongoing tariff dispute with China and currency-driven competitive pressures in Japan have disrupted sales planning and forecasting, particularly in Asia.
Regulatory Hurdles: MDR certification delays for the IRIDEX PASCAL system are negatively affecting retina sales throughout Europe, creating pent-up demand that cannot be immediately addressed.
Economic Uncertainties: Japan's sluggish market, driven by the weak yen against the U.S. dollar, benefits domestic competitors and creates challenges for IRIDEX's operations in the region.
Strategic Execution Risks: The transition to third-party contract manufacturers has led to a one-time inventory write-down, highlighting risks in production transfer and resource planning. Additionally, the company is relocating certain administrative functions outside of California, which may pose operational challenges during the transition.
Competitive Pressures: Domestic competitors in Japan are benefiting from currency fluctuations, creating a challenging environment for IRIDEX. Additionally, the company faces volatility in Asia due to macroeconomic factors.
Cash Flow and Profitability: The company is on track to achieve positive cash flows in the fourth quarter of 2025 and positive adjusted EBITDA for the full year 2025. Additionally, the company expects to sustain cash flow positive operations in 2026.
Cost Reduction Initiatives: The company is negotiating with contract manufacturers to reduce the cost of goods sold and improve gross margins. These changes are expected to take time to implement but are anticipated to positively impact financial performance in 2026. Relocation of certain general and administrative functions outside of California is expected to generate approximately $165,000 in quarterly savings starting in Q1 2026.
Glaucoma Business Growth: The company is leveraging its installed base of G6 systems to drive higher utilization and is utilizing a sales enablement platform to increase procedure volumes. Internationally, the company sees strong growth potential in Europe, the Middle East, Africa, and Latin America, despite challenges in Asia due to tariff disputes and currency fluctuations.
Retina Product Portfolio: The company is focusing on broader adoption of its PASCAL system and securing additional international regulatory approvals for next-generation retina platforms. This is expected to capitalize on a robust global distribution network and drive growth in the retina segment.
The selected topic was not discussed during the call.
The earnings call shows mixed signals: positive revenue growth and strategic initiatives, but concerns about supply chain disruptions and competitive pressures. While there is a clear path to profitability, the current financials show a net loss and reduced gross margins. The absence of clear shareholder return plans and the absence of positive analyst sentiment in the Q&A further support a neutral outlook. Without market cap data, the stock's sensitivity to these factors is uncertain, suggesting a neutral prediction for the stock price over the next two weeks.
The earnings call summary indicates positive trends, such as achieving adjusted EBITDA positivity, cost reductions, and revenue growth. The strategic partnership with Novel Inspiration and focus on expense management are promising. While risks and uncertainties exist, including regulatory and partnership risks, the Q&A reveals minimal impact from tariffs and plans for cash flow positivity. Despite unchanged EPS, the overall sentiment is positive due to operational improvements and strategic initiatives, suggesting a likely stock price increase of 2% to 8%.
The earnings call shows strong financial improvement with positive adjusted EBITDA and reduced operating expenses. Despite a net loss, the company is on track for cash flow breakeven in 2025. The strategic investment and increased gross margin are positive signs. However, management's refusal to provide specific revenue targets and ongoing risks like supply chain challenges temper enthusiasm. Overall, the sentiment is positive, with expected growth driven by new product launches and market demand.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
